2 active not recruiting, 2 not yet recruiting, 2 recruiting, 2 unknown. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 2, Not yet recruiting 2, Recruiting 2, Unknown 2 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow T-cell Acute Lymphoblastic Lymphoma: new trials by email Literature Review of T-cell Acute Lymphoblastic Lymphoma trials Research Report on T-cell Acute Lymphoblastic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-11-02 |
| Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells CD7.CAR/28zeta T Cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-05-12 | 2026-05-18 |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma Daratumumab - T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma | Phase 1 | Recruiting | New York Medical College | 30 | 2023-05-22 | 2026-09-11 |
| Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells CD7.CAR/28zeta CAR T cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 45 | 2021-08-02 | 2026-10-02 |
| Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances CD7 CAR T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2020-12-01 | 2021-06-22 |
| Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies ThisCART7 cells - T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma | Phase 1 | Unknown | Fundamenta Therapeutics, Ltd. | 30 | 2020-01-22 | 2021-11-19 |
| Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 104 | 2017-11-01 | 2026-11-04 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia, Myeloid, Acute (2) · Lymphoma, T-Cell (2) · Lymphoma (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Leukemia (8) · Leukemia, Lymphoid (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia, Myeloid (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma (1)
daratumumab (1)
Baylor College of Medicine (3) · Shenzhen Geno-Immune Medical Institute (2) · Fundamenta Therapeutics, Ltd. (1) · New York Medical College (1) · iCell Gene Therapeutics (1)
China (4) · United States (4)
Rayne Rouce, MD (3) · LaQuisa Hill, MD (2) · Allyson Flower, MD (1) · Hongyu Zhang (1) · Mitchell Cairo, MD (1) · Troy Quigg, DO (1) · Wang Xingbing (1)
PMID 34274536, PMID 36086817, PMID 36858787
P50CA126752 (1)